1. ^{{Cite web|title = Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test|url = https://www.forbes.com/sites/matthewherper/2015/04/14/biogen-ms-drug-results-are-mildly-encouraging-in-eye-disease-test/|website = Forbes|accessdate = 2015-10-13}}
2. ^{{Cite web|title = Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex|url = https://clinicaltrials.gov/ct2/show/NCT01864148|website = Clinical Trials|accessdate = 2015-10-13}}
3. ^{{Cite journal|title = Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033|url = http://nn.neurology.org/content/1/2/e18|journal = Neurology - Neuroimmunology Neuroinflammation|date = 2014-08-01|issn = 2332-7812|pmc = 4202679|pmid = 25340070|pages = e18|volume = 1|issue = 2|doi = 10.1212/NXI.0000000000000018|first = Jonathan Q.|last = Tran|first2 = Jitesh|last2 = Rana|first3 = Frederik|last3 = Barkhof|first4 = Isaac|last4 = Melamed|first5 = Hakop|last5 = Gevorkyan|first6 = Mike P.|last6 = Wattjes|first7 = Remko de|last7 = Jong|first8 = Kristin|last8 = Brosofsky|first9 = Soma|last9 = Ray}}